Articles scientifiques

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Auteurs : Janssens A, Berneman ZN, Offner F, Snauwaert S, Mineur P, Vanstraelen G, Meers S, Spoormans I, Bron D, Vande Broek I, Van Bogaert C, De Beleyr B, Smet A, Nielsen L, Wapenaar R, André M
Année : 2022
Journal : Clin Hematol Int
Volume : 4
Pages : 133-143

CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.

Auteurs : Karam A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H, Kazzi H, Albisinni S, Roumeguère T
Année : 2022
Journal : Cancer Invest
Pages : 1-15

Non-invasive imaging of a rare presentation of infantile generalized eruptive histiocytosis with xanthogranuloma-like appearance: dermoscopy, reflectance confocal microscopy, and line-field optical coherence tomography.

Auteurs : Bruzziches F, Tognetti L, Habougit C, Suppa M, Del Marmol V, Cinotti E, Rubegni P, Perrot JL
Année : 2022
Journal : Int J Dermatol
Volume : 61
Pages : e288-e290

Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.

Auteurs : Orte Cano C, Van Meerhaeghe T, Tannous J, Lienard D, Van Gestel D, Cuylits N, Luce S, Carlot S, Le Moine A, Aspeslagh S, Del Marmol V
Année : 2022
Journal : J Eur Acad Dermatol Venereol
Volume : 36 Suppl 1
Pages : 53-58

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Auteurs : Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A
Année : 2022
Journal : J Clin Oncol
Volume : 28
Pages : 3246-3256

Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity.

Auteurs : Berretta M, Dal Lago L, Tinazzi M, Ronchi A, La Rocca G, Montella L, Di Francia R, Facchini BA, Bignucolo A, Montopoli M
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Primary invasive ductal carcinoma of axillary accessory breast.

Auteurs : Nguyen TH, El-Helou E, Pop CF, Shall A, Zaiter M, Naccour J, Ho XD, Nguyen TTH, Nguyen TMC, Bui TT, Nguyen VC, Hoang H
Année : 2022
Journal : Int J Surg Case Rep
Volume : 98
Pages : 107597

Code of practice needed for samples donated by trial participants.

Auteurs : Coleman R, Chan A, Barrios C, Cameron D, Costa L, Dowsett M, Harrison D, Howell A, Lacombe D, MacKenzie M, Martin M, McIntosh S, Morgan A, Piccart-Gebhart M, Spanic T
Année : 2022
Journal : Lancet Oncol
Volume : 23
Pages : e89-e90

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.

Auteurs : Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP
Année : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 2762-2770

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium^☆.

Auteurs : Charlier F, Descamps T, Lievens Y, Geets X, Remouchamps V, Lambrecht M, Moretti L
Année : 2022
Journal : Radiother Oncol
Volume : 167
Pages : 57-64

Pristine submucosal visibility using Texture and Color Enhancement Imaging during saline-immersion rectal endoscopic submucosal dissection.

Auteurs : Lemmers A, Bucalau AM, Verset L, Devière J
Année : 2022
Journal : Endoscopy
Volume : 54
Pages : E310-E311

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.

Auteurs : Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Sallé F, Blanquart C, van Meerbeeck JP, Berghmans T, Jean D, Roger PP
Année : 2022
Journal : Mol oncol

Morphological evaluation of melanocytic lesions with three-dimensional line-field confocal optical coherence tomography: correlation with histopathology and reflectance confocal microscopy. A pilot study.

Auteurs : Perez-Anker J, Puig S, Alos L, García A, Alejo B, Cinotti E, Orte Cano C, Tognetti L, Lenoir C, Monnier J, Machuca N, Castillo P, Gibert PR, Rubegni P, Suppa M, Perrot JL, Del Marmol V, Malvehy J
Année : 2022
Journal : Clin Exp Dermatol
Volume : 47
Pages : 2222-2233

Genomics of metastatic breast cancer

Auteurs : Geukens T, De Schepper M, Richard F, Maetens M, Van Baelen K, Leduc S, Isnaldi E, Nguyen HL, Bachir I, Vandenberghe E, Van den Bogaert W, Punie K, Neven P, Wildiers H, Floris G, Desmedt C
Année : 2022
Journal : Belgian J Medical Oncology
Volume : 16(1)
Pages : 18-28

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.

Auteurs : Bachir B, Anouti S, Abi Jaoude J, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan YH
Année : 2022
Journal : Int J Radiat Oncol Biol Phys
Volume : 113
Pages : 135-142

Why novel mRNA modifications are so challenging and what we can do about it.

Auteurs : Penning A, Jeschke J, Fuks F
Année : 2022
Journal : Nat Rev Mol Cell Biol
Volume : 23
Pages : 385-386

Dealing with Macrophage Plasticity to Address Therapeutic Challenges in Head and Neck Cancers.

Auteurs : Furgiuele S, Descamps G, Cascarano L, Boucq A, Dubois C, Journe F, Saussez S
Année : 2022
Journal : Int J Mol Sci
Volume : 23

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Auteurs : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the My Personal Breast Screening" (MyPeBS) randomised clinical trial."

Auteurs : Roux A, Cholerton R, Sicsic J, Moumjid N, French DP, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Castells X, Ritchie D, Keatley D, Baron C, Delaloge S, de Montgolfier S
Année : 2022
Journal : BMC Cancer
Volume : 22
Pages : 507

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.

Auteurs : Spira A, Awada A, Isambert N, Lorente D, Penel N, Zhang Y, Ojalvo LS, Hicking C, Rolfe PA, Ihling C, Dussault I, Locke G, Borel C
Année : 2022
Journal : Front Oncol
Volume : 12
Pages : 981940